Immatics NV
NASDAQ:IMTX

Watchlist Manager
Immatics NV Logo
Immatics NV
NASDAQ:IMTX
Watchlist
Price: 7.07 USD 3.21% Market Closed
Market Cap: 843.9m USD
Have any thoughts about
Immatics NV?
Write Note

Immatics NV
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Immatics NV
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
Immatics NV
NASDAQ:IMTX
Additional Paid In Capital
€823.2m
CAGR 3-Years
15%
CAGR 5-Years
193%
CAGR 10-Years
N/A
BioNTech SE
NASDAQ:BNTX
Additional Paid In Capital
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
MorphoSys AG
XETRA:MOR
Additional Paid In Capital
€927.8m
CAGR 3-Years
7%
CAGR 5-Years
8%
CAGR 10-Years
12%
CureVac NV
NASDAQ:CVAC
Additional Paid In Capital
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biotest AG
XETRA:BIO
Additional Paid In Capital
€219.8m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
0%
Formycon AG
XETRA:FYB
Additional Paid In Capital
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Immatics NV
Glance View

Market Cap
843.9m USD
Industry
Biotechnology

Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 188 full-time employees. The firm is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The firm develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.

IMTX Intrinsic Value
4.39 USD
Overvaluation 38%
Intrinsic Value
Price

See Also

What is Immatics NV's Additional Paid In Capital?
Additional Paid In Capital
823.2m EUR

Based on the financial report for Dec 31, 2023, Immatics NV's Additional Paid In Capital amounts to 823.2m EUR.

What is Immatics NV's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
193%

Over the last year, the Additional Paid In Capital growth was 15%. The average annual Additional Paid In Capital growth rates for Immatics NV have been 15% over the past three years , 193% over the past five years .

Back to Top